Medicine
Perioperative Management of Patients on Anticoagulant Therapy
Quick fact
Up to 10% of patients on chronic anticoagulation require surgery or an invasive procedure each year, and their management demands a meticulous balance of risks.
Why this is interesting
Your patient is taking warfarin and needs surgery tomorrow. Should you just stop the drug and hope nothing goes wrong? The answer could mean the difference between a safe operation and a life-threatening clot.
Read the full explanation
Understanding Perioperative Management of Patients on Anticoagulant Therapy
Imagine you're walking a tightrope: on one side is the risk of a blood clot (thrombosis) that could cause a stroke or pulmonary embolism, and on the other is the risk of bleeding heavily during surgery. When a patient takes anticoagulants, their blood is slower to clot, which is great for preventing thrombosis but dangerous during an operation. The goal is to temporarily reduce the anticoagulant effect for the surgery, then restore it as soon as it's safe. For warfarin, this means stopping the drug several days before surgery to allow the INR (a measure of clotting time) to fall to a safe level. For newer DOACs (like rivaroxaban), the process is shorter because they clear the body faster. In some cases, 'bridging' is used: the patient stops warfarin but takes a short-acting injectable heparin (LMWH) until just before surgery, so that they are never unprotected. After surgery, the question is when to restart: too soon risks bleeding, too late risks clots. The decision is based on the patient's individual risk of thrombosis (e.g., prior clots, mechanical heart valve) versus their risk of bleeding (e.g., type of surgery).
A deeper explanation
The mechanism of perioperative management hinges on the pharmacology of the anticoagulant. Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X), leading to a slow onset and offset (half-life around 36-42 hours). Therefore, it must be stopped 5 days before surgery to bring INR below 1.5 for most surgeries. DOACs directly inhibit specific clotting factors (thrombin or factor Xa) and have short half-lives (around 8-15 hours), so they need to be stopped only 2-3 days before surgery, depending on renal function. The rationale for bridging is that LMWH has a half-life of only 4-6 hours, so it can be given up to 24 hours before surgery, and restarted soon after (usually 24-72 hours) if hemostasis is secure. The decision to bridge is based on the patient's thromboembolic risk: for example, those with mechanical mitral valves or recent DVT are high risk, so bridging is recommended, whereas those with atrial fibrillation and a low CHA2DS2-VASc score may not need it. Postoperatively, the timing of resumption aims to minimize the window of vulnerability while avoiding surgical bleeding. For high-bleeding-risk surgeries, anticoagulants may be held for 48-72 hours and even longer if there is ongoing bleeding. This balance is delicate: the 'bridge' is like a relay race where the baton must pass smoothly from one runner (warfarin) to another (heparin) and back, without dropping it (a clot) or tripping (bleeding).